Xeris Biopharma to Report Second Quarter 2023 Financial Results on August 8, 2023
01 August 2023 - 9:00PM
Business Wire
Conference call and webcast at 8:30am ET
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented
biopharmaceutical company committed to improving patients’ lives by
developing and commercializing innovative products across a range
of therapies, today announced that the Company will release its
second quarter 2023 financial results before the open of the U.S.
financial markets on Tuesday, August 8, 2023. Management will host
a conference call and webcast at 8:30 a.m. Eastern Time that day to
discuss the Company’s financial and operational results.
To pre-register for the call, please go to the following link:
https://www.netroadshow.com/events/login?show=73c6056b&confId=53289
After registering, a confirmation email will be sent, including
dial-in details and a unique code for entry. The Company recommends
registering a minimum of ten minutes prior to the start of the
call. Following the conference call, a replay will be available
until Tuesday, August 22, 2023 at US:1 929 458 6194, US Toll Free:
1 866 813 9403, UK: 0204 525 0658, Canada: 1 226 828 7578, or all
other locations: +44 204 525 0658 Access Code: 729515
To join the webcast, please visit “Events” on investor relations
page of the Company’s website at www.xerispharma.com or use this
link: https://events.q4inc.com/attendee/901721849
About Xeris Biopharma Holdings, Inc.
Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical
company committed to improving patients’ lives by developing and
commercializing differentiated and innovative products across a
range of therapies. Xeris has three commercially available
products: Gvoke®, a ready-to-use liquid glucagon for the treatment
of severe hypoglycemia; Keveyis®, a proven therapy for primary
periodic paralysis; and Recorlev® for the treatment of endogenous
Cushing’s syndrome. Xeris has a diverse pipeline of development and
partnered programs using its formulation sciences, XeriSol™ and
XeriJect™, to support long-term product development and commercial
success.
Xeris Biopharma Holdings is headquartered in Chicago, IL. For
more information, visit www.xerispharma.com, or follow us on
Twitter, LinkedIn or Instagram.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230731056974/en/
Investor Contact Allison Wey Senior Vice President,
Investor Relations and Corporate Communications
awey@xerispharma.com
Xeris Biopharma (NASDAQ:XERS)
Historical Stock Chart
From Apr 2024 to May 2024
Xeris Biopharma (NASDAQ:XERS)
Historical Stock Chart
From May 2023 to May 2024